A Parkinson's Disease programme at Stem Plus in Sofia is €3,000–€8,000, versus roughly €14,600–€46,000 in the Netherlands. About 2.9h from Amsterdam, inside the EU, visa-free.
If you are researching Parkinson's Disease treatment from the Netherlands, the obstacle is usually access or cost: standard options have plateaued, and regenerative therapy at home runs to €14,600–€46,000. Stem Plus offers the same European GMP standard for a fraction of that — and an easy, mostly visa-free trip.
Parkinson's disease results from progressive loss of dopamine-producing neurons in the substantia nigra. Stem-cell research pursues two complementary routes: neurogenic cells differentiated toward dopamine neurons are studied to replace lost cells and restore dopamine signalling, while placental mesenchymal stem cells are explored for neuroprotection — slowing degeneration through anti-inflammatory and growth-factor secretion. Preclinical evidence suggests dopamine-releasing cells can reinnervate the striatum and that trophic factors may delay neuronal death. Key challenges are achieving cell survival, integration and functional restoration in a degenerating brain. Most trials are early-phase, with modest motor changes reported. It is delivered under a physician-led protocol and designed to complement your existing care.
| Netherlands (home) | Stem Plus · EU | |
|---|---|---|
| Parkinson's Disease treatment | €14,600–€46,000 | €3,000–€8,000 |
| Regulation | varies | EU · GMP |
| Flight to Sofia | 2.9h from Amsterdam | — |
This note is general information for planning, not legal or medical advice. Confirm entry rules for your nationality before booking.
Cost ranges are indicative market figures for planning, not quotes.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment